Stifel Nicolaus Issues Pessimistic Forecast for Beta Bionics (NASDAQ:BBNX) Stock Price

Beta Bionics (NASDAQ:BBNX) had its price objective dropped by equities researchers at Stifel Nicolaus from $31.00 to $25.00 in a research report issued on Wednesday, Marketbeat reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ target price suggests a potential upside of 88.82% from the company’s previous close.

BBNX has been the topic of a number of other research reports. Truist Financial reduced their target price on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a research note on Monday. TD Cowen began coverage on Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 price target for the company. The Goldman Sachs Group restated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a research report on Thursday, January 15th. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, Robert W. Baird set a $28.00 target price on shares of Beta Bionics in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $26.64.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $13.24 on Wednesday. The firm’s 50-day moving average is $24.60 and its two-hundred day moving average is $22.56. The company has a market capitalization of $582.96 million and a PE ratio of -3.03. Beta Bionics has a 12-month low of $8.89 and a 12-month high of $32.71.

Insider Buying and Selling at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the sale, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mike Mensinger sold 2,200 shares of Beta Bionics stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares of the company’s stock, valued at $2,430,635.20. This trade represents a 2.65% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 32,490 shares of company stock worth $960,835 in the last 90 days.

Institutional Investors Weigh In On Beta Bionics

Several hedge funds have recently modified their holdings of BBNX. GPS Wealth Strategies Group LLC grew its holdings in Beta Bionics by 45.0% in the third quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Beta Bionics by 203.6% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the last quarter. Verition Fund Management LLC boosted its holdings in shares of Beta Bionics by 4.0% in the 3rd quarter. Verition Fund Management LLC now owns 47,299 shares of the company’s stock valued at $940,000 after purchasing an additional 1,823 shares during the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Beta Bionics by 139.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after buying an additional 1,863 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Beta Bionics by 10.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,558 shares of the company’s stock worth $343,000 after buying an additional 2,205 shares during the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.